Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
h7n9 inactivated whole-virus influenza vaccine
- Development stage
- Unknown
- Lead developer
- Hualan Biological Bacterin
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The H7N9 inactivated whole-virus influenza vaccine is a monovalent prophylactic vaccine candidate developed by Hualan Biological Bacterin for the prevention of avian influenza A (H7N9) infection. Unlike split-virion vaccines, this formulation utilizes the entire inactivated virus particle, which is intended to provide robust immunogenicity in populations with little to no pre-existing immunity to the H7N9 subtype. The vaccine works by presenting the viral hemagglutinin (HA) and neuraminidase (NA) antigens to the immune system, thereby inducing the production of neutralizing antibodies. Hualan Biological has advanced this candidate through Phase II clinical testing in China (e.g., trial CTR20170834), evaluating its safety, tolerability, and immunogenic profile in healthy subjects aged 12 years and older.
- Other names
- H7N9 whole-virion inactivated vaccineH-7N9 whole-virion inactivated vaccineH 7N9 whole-virion inactivated vaccineinactivated whole-virus H7N9 influenza vaccineH7N9 inactivated whole-virus influenza vaccineH-7N9 inactivated whole-virus influenza vaccineH 7N9 inactivated whole-virus influenza vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on h7n9 inactivated whole-virus influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on h7n9 inactivated whole-virus influenza vaccine.